Auto Amazon Links: No products found. Blocked by captcha.
The UK Health Security Agency (UKHSA) has confirmed that the recent meningitis outbreak in Kent involves the Meningitis B strain, a serious infection affecting the protective membranes around the brain and spinal cord. Tragically, two individuals have died as a result: an 18-year-old schoolgirl from Faversham named Juliette, and a 21-year-old student attending the University of Kent. Alongside these fatalities, 11 others have been hospitalized following 13 reported cases exhibiting symptoms of meningitis and septicaemia between Friday and Sunday in the Canterbury area.
In response to the outbreak, the agency has issued advice urging anyone who visited Club Chemistry in Canterbury on March 5th, 6th, or 7th to seek preventive antibiotic treatment as a precaution. Additionally, over 30,000 students, staff, and their families in Canterbury are being contacted to raise awareness and offer medical support. The strain responsible, Meningitis B (MenB), is reported to be behind the majority of meningococcal disease cases across the UK. Official statistics indicate that during the most recent full year, 2024-2025, there were 378 instances of invasive meningococcal disease nationwide.
Meningitis, particularly invasive bacterial meningitis, poses a significant health risk because the infection can enter the bloodstream or brain linings, leading to life-threatening conditions such as sepsis. While meningitis can occur at any age, infants, young children, teenagers, and young adults are the groups most vulnerable to severe infections. Vaccinations play a crucial role in prevention: the MenACWY vaccine protects teenagers against meningococcal groups A, C, W, and Y, and is routinely offered at age 14. Meanwhile, the MenB vaccine is administered primarily to babies, starting at eight weeks old, with follow-up doses in early infancy and a booster at one year.
Despite calls to extend MenB vaccination to teenagers, the NHS currently does not provide a catch-up vaccine program for this group. This decision is based on research suggesting the MenB vaccine has limited impact on transmission, does not cover all meningococcal B strains, and offers a relatively short duration of protection. Consequently, UK vaccine experts have concluded it is not cost-effective to offer this vaccine routinely to adolescents, although some parents have opted to obtain it privately for their teenagers.
Symptoms of meningitis can emerge suddenly
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.